Biocon Limited – Product Pipeline Review

Global Markets Direct’s, ‘Biocon Limited – Product Pipeline Review – 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited

The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Biocon Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Biocon Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Biocon Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Biocon Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Biocon Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Biocon Limited Snapshot 5

Biocon Limited Overview 5

Key Facts 5

Biocon Limited - Research and Development Overview 6

Key Therapeutic Areas 6

Biocon Limited - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Biocon Limited - Pipeline Products Glance 13

Biocon Limited - Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13

Phase III Products/Combination Treatment Modalities 14

Biocon Limited - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Biocon Limited - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Biocon Limited - Drug Profiles 18

adalimumab biosimilar - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

bevacizumab biosimilar - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

BVX-20 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

etanercept biosimilar - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

filgrastim - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

insulin aspart - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

insulin glargine - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

insulin human - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

insulin lispro - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

insulin tregopil - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

itolizumab - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibody Conjugates for Oncology and Infectious Disease - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

pegfilgrastim - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

trastuzumab biosimilar - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Biocon Limited - Pipeline Analysis 36

Biocon Limited - Pipeline Products by Target 36

Biocon Limited - Pipeline Products by Route of Administration 38

Biocon Limited - Pipeline Products by Molecule Type 39

Biocon Limited - Pipeline Products by Mechanism of Action 40

Biocon Limited - Dormant Projects 42

Biocon Limited - Company Statement 43

Biocon Limited - Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Biocon Limited, Key Facts 5

Biocon Limited – Pipeline by Indication, 2016 8

Biocon Limited – Pipeline by Stage of Development, 2016 9

Biocon Limited – Monotherapy Products in Pipeline, 2016 10

Biocon Limited – Partnered Products in Pipeline, 2016 11

Biocon Limited – Partnered Products/ Combination Treatment Modalities, 2016 12

Biocon Limited – Pre-Registration, 2016 13

Biocon Limited – Phase III, 2016 14

Biocon Limited – Phase II, 2016 15

Biocon Limited – Phase I, 2016 16

Biocon Limited – Preclinical, 2016 17

Biocon Limited – Pipeline by Target, 2016 37

Biocon Limited – Pipeline by Route of Administration, 2016 38

Biocon Limited – Pipeline by Molecule Type, 2016 39

Biocon Limited – Pipeline Products by Mechanism of Action, 2016 41

Biocon Limited – Dormant Developmental Projects,2016 42

Biocon Limited, Other Locations 48

Biocon Limited, Subsidiaries 48

List of Figures

List of Figures

Biocon Limited – Pipeline by Top 10 Indication, 2016 7

Biocon Limited – Pipeline by Stage of Development, 2016 9

Biocon Limited – Monotherapy Products in Pipeline, 2016 10

Biocon Limited – Partnered Products in Pipeline, 2016 11

Biocon Limited – Pipeline by Target, 2016 36

Biocon Limited – Pipeline by Route of Administration, 2016 38

Biocon Limited – Pipeline by Molecule Type, 2016 39

Biocon Limited – Pipeline Products by Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports